Landmark Bio

Are you attending Alliance for Regenerative Medicine’s 2025 Cell & Gene Meeting on the Med? Connect with Landmark Bio’s Ran Zheng, Todd Howren, Ph.D. and Kris Ward while on-site through the partnering system! https://lnkd.in/e5KMn8yh Looking forward to connecting with sector leaders to tackle the most pressing issues facing cell and gene therapy. See you in Rome! #CGMed25 #cellandgenetherapy

We had a wonderful time with Artis BioSolutions this week! We are excited for this new chapter and the opportunities it presents to better serve our partners and patients.

We are excited to announce that Landmark Bio is now part of Artis BioSolutions! This acquisition, supported by initial funding from Oak HC/FT, marks a significant milestone, enabling us to scale our capabilities and accelerate the development and manufacturing of advanced therapies.   Artis BioSolutions is a newly formed company focused on optimizing the discovery, process development, and manufacturing of genetic medicines.   We are incredibly excited about this new chapter and the opportunities it presents to better serve our partners and patients. Thank you for your continued support!   Read the full press release at: https://lnkd.in/gpNPFEYv   #AdvancedTherapies #Manufacturing #Biotech #Acquisition #Lifesciences #Innovation #CellTherapy #GeneTherapy #ArtisBioSolutions #LandmarkBio

Did you know that a significant portion of delays in clinical development stems from Chemistry, Manufacturing, and Controls (CMC) issues? At Landmark Bio, we believe in the power of proactive planning, that's why we stress the importance of establishing your regulatory and CMC strategies early in the development process Michael Covington, CQRO and Gregg Nyberg, CTO shared insights during an Outsourced Pharma webinar on how to overcome CMC challenges in cell & gene therapy—covering everything from how to translate protocols into robust manufacturing processes using Quality by Design principles, scaling your manufacturing to meet anticipated market demand, and ensuring comparability to confirm your product's commercial readiness. If you missed the live session, don’t worry—the full webinar is now available to watch: https://lnkd.in/eTyUbtJN

🚀 POSTmark features mirrored R&D and cGMP equipment, along with processes that are designed to seamlessly support all stages of development, from early-stage R&D through to commercial cGMP manufacturing.   Our platform enables: 🔬 Rapid Transition: Move from R&D to cGMP scale in record time (6-9 months for cGMP AAV). 💡 Streamlined Development: Research-grade AAV that mirrors cGMP AAV, ensuring consistency at every stage. 💰 Cost and Risk Reduction: Minimize time, costs, and risks with an optimized process that accelerates your journey to market. Whether you're working on viral vector production or gene therapy, POSTmark offers a proven, scalable solution to bring your innovations to life faster and more efficiently. Read more about our Drug Development Services for Viral Vectors, including AAV here:   #Biotech #CellAndGeneTherapy #cGMP #Innovation #BiotechManufacturing #ScaleUp #Biopharma #LifeSciences #BiotechInnovation

We're thrilled to announce that ChromaTan, Inc Inc. and Landmark Bio have been awarded a grant from the NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). This funding will support the development of an intensified recombinant adeno-associated virus (rAAV) production process, advancing gene therapy manufacturing. This collaboration leverages Landmark Bio’s expertise in viral vector process development, chemistry, manufacturing and controls (CMC), and GMP manufacturing.   Click here to read the full press release: https://lnkd.in/gpNPFEYv We look forward to working with ChromaTan and contributing to the NIIMBL mission and community! #GeneTherapy #Manufacturing #NIIMBL #LandmarkBio #Innovation #Biopharmaceuticals

🚀 At Landmark Bio, our Platform Optimized for Scale-up and Transfer (POSTmark) is a game-changer for the biotech industry. Our platform enables: 🔬 Rapid Transition: Move from R&D to cGMP scale in record time (6-9 months for cGMP LVV). 💡 Streamlined Development: Research-grade LVV that mirrors cGMP LVV, ensuring consistency at every stage. 💰 Cost and Risk Reduction: Minimize time, costs, and risks with an optimized process that accelerates your journey to market.   Whether you're working on viral vector production or gene therapy, POSTmark offers a proven, scalable solution to bring your innovations to life faster and more efficiently.   Read more about our Drug Development Services for Viral Vectors, including LVV here: https://lnkd.in/eUQ84dfg   #Biotech #CellAndGeneTherapy #cGMP #Innovation #R&D #BiotechManufacturing #ScaleUp #Biopharma #LifeSciences #BiotechInnovation

Today, we celebrate the incredible women who have shaped our past, are leading in the present, and will continue to inspire the future. From leaders in business, science, technology, and the arts to the everyday women who make a difference, this day serves as a reminder of how far we've come—and how much further we can go together! Let's commit to lifting the voices of women around the world, creating more inclusive workplaces, and fostering an environment where all women can thrive! #InternationalWomensDay #IWD2025 #WomenInLeadership #Empowerment #WomenInSTEAM #AccelerateAction

🌍 Today, let's raise our voices and spread awareness for those living with rare diseases. By sharing stories, supporting research, and advocating for better access to care and treatment, we can create a world that values every patient, no matter how rare their condition may be. Let’s continue pushing for innovations in medical care, research funding, and policy changes that will make a lasting impact! To learn more about how you can get involved, please visit: https://lnkd.in/gk6hbAF #RareDiseaseDay #PatientAdvocacy #TogetherWeCan

Landmark Bio’s Associate Vice President & Quality Site Head, Mike Sousa, Associate Vice President of Process & Analytical Development, Eli Kraus, and Senior Director of Analytical Sciences, Manish Tandon, recently published an article entitled, Integrating Analytical Method Development and Quality Control: A Roadmap for Successful Advanced Therapy Development. Aligning and integrating Analytical Method Development (AMD) and Quality Control (QC) activities is crucial to the drug product life cycle. This collaboration ensures a smooth method transfer and brings numerous benefits that can drive the successful development and commercialization of the drug product. To read further, please follow the link: https://lnkd.in/ezBdEnHJ #AnalyticalMethodDevelopment #QualityControl #CellandGeneTherapies